Atopic DermatitisPhase 2NCT07599813

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 2 study testing Camoteskimab in people with Atopic Dermatitis and Atopic, run by Apollo Therapeutics Ltd at 85 sites in 8 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study. Read more about this study

Who is it for?: Ages 18 to 65 years
Conditions the study is for: Atopic Dermatitis, Atopic, Dermatitis
What is being tested?: Camoteskimab
Type of treatment: Injection or infusion
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 280 participants
Where: 85 sitesin 8 countries
Study dates: 28 May 2026to 30 Apr 2028
Phase: Phase 2
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age 18-65 inclusive, at the time of signing the informed consent.
Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.
Participants with moderate-to-severe AD defined by:
Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline.
AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline.
EASI score of ≥ 16 at Screening and at Baseline.

Show all 10Show fewer

Peak pruritus numerical rating scale (PP-NRS) ≥ 4 at Baseline. Note: The PP-NRS will be calculated from the 7 consecutive days immediately preceding Baseline. A minimum of 4 daily scores out of the 7 days is needed.
Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks.
Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Participant provides signed informed consent

Who cannot join

History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.
Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.
Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.
Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.
Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement.
Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes.

Show all 35Show fewer

Participant has severe and uncontrolled seasonal or allergic rhinitis, severe and uncontrolled asthma or any other severe and uncontrolled atopic disease as judged by the Investigator.
Treatment of AD with medicated moisturizers available only by prescription within 2 weeks prior to the Baseline visit.
Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test.
Active hepatitis B virus (HBV): hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+) confirmed by HBV PCR positive (+).
Active hepatitis C virus (HCV): If hepatitis C antibody positive (+), confirmed by HCV RNA test. Note: a participant with documented proof of cure from HCV may be enrolled.
Evidence of active or latent tuberculosis.
Receipt of live or attenuated live vaccine within 6 weeks prior to screening.
Participant had a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study.
Participant is known to have immune deficiency or is immunocompromised
Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of:
Completely resected basal cell or squamous cell carcinoma of the skin.
Carcinoma in situ of the cervix.
Has had previous exposure to anti-IL-18 therapy.
Known allergy/sensitivity to any component of IMP.
History of use of any of these medications as follows:
Dupilumab, tralokinumab, lebrikizumab, nemolizumab within 8 weeks prior to Baseline.
Systemic JAKi within 4 weeks prior to Baseline.
Any topical medicated treatment that could affect AD within 2 weeks prior to Baseline, including, but not limited to, topical corticosteroids, topical phosphodiesterase (PDE4) inhibitors, topical calcineurin inhibitors, topical JAKi, tars, antimicrobials, medical devices, and bleach baths.
Systemic therapies (other than biologics) that could affect AD not noted above, within 4 weeks prior to Baseline, including but not limited to, retinoids, calcineurin inhibitors, methotrexate, hydroxycarbamide (hydroxyurea), azathioprine, oral/injectable corticosteroids. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.
Treatment with any investigational biologic agent or biologic agent approved after publication of this protocol, within 12 weeks (or 5 half-lives, whichever is greater) of screening.
Treatment with any investigational nonbiologic agent, or any investigational device or procedure, within 4 weeks (or 5 half-lives, whichever is greater) of screening.
UV-B phototherapy (including tanning beds) or excimer laser use within 4 weeks prior to Baseline or during the study.
PUVA treatment within 4 weeks prior to Baseline
Sedating antihistamines, including but not limited to doxepin, hydroxyzine or diphenhydramine within 1 week prior to Baseline
Topical products containing urea within 1 week prior to Baseline
Systemic antibiotics within 2 weeks or topical antibiotics within 1 week prior to Baseline
Intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Baseline.
Female participant who is pregnant or breastfeeding or trying to conceive.
Participant considered unlikely to adhere to treatment and/or follow the protocol in the opinion of the Investigator.

Trial locations and contacts

85 sites in 8 countries. Contact the study team or a site near you to ask about taking part.

Country

City, postcode or hospital

Sites recruiting now only

85 sites in 8 countries

United States33 sites, 33 recruiting

AllerVie Clinical Research
Birmingham, Alabama, 35209
Kendra Williams, 205-209-4101, ACRAdmin@allervie.com
Recruiting
Cahaba Dermatology and Skin Health Center
Birmingham, Alabama, 35244
Jennifer Perry, 205-778-1564, jperry@cahabaderm.com
Recruiting
Dermatology Trial Associates, Inc
Bryant, Arkansas, 72022
Tim Dugan, 501-655-6138, tdugan@burkepharmaceutical.com
Recruiting
Best Skin Research, LLC
Camp Hill, Pennsylvania, 17011
Erin McDonald, 717-385-5426, erin@bestskinresearch.com
Recruiting
ABMED Clinical Research Corp.
Cape Coral, Florida, 33904
Jorge Remedios, 239-471-7595, jorger@abmedclinicalresearch.com
Recruiting
DS Research of Southern Indiana,LLC
Clarksville, Indiana, 47129
Megan Vissing, 812-213-9769, mvissing@dsresearch.com
Recruiting
Trail Horizon
Clifton, New Jersey, 07013
Chirag Patel, 732-798-0301, cpatel@trialhorizon.com
Not yet recruiting
ClinOhio Research Services
Columbus, Ohio, 43213
Kelly Thomas, 614-683-5800, Kthomas@clinohioresearch.com
Recruiting
Red River Research Partners, LLC
Fargo, North Dakota, 58103
Gunar Loftsgard, 701-997-1510, gunar@redriverresearchpartners.com
Recruiting
Skin Care Research
Hollywood, Florida, 33021
Kimberly Gardner, 954-674-3535, Kgardner@dermcaremgt.com
Recruiting
Marvel Research, LLC
Huntington Beach, California, 92648
Mathew Campos, 714-375-5970, mcampos@marvelclinical.com
Recruiting
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250
Joannie Prusa, 317-516-5030, jprusa@ecommunity.com
Recruiting
Metropolis Dermatology
Los Angeles, California, 90025
Jayda Pham, 424-393-0005, jayda.pham@metropolisderm.com
Recruiting
Dermatology Research Associates
Los Angeles, California, 90048
Nadia Trejo, 310-337-7171, ntrejo@drsofen.com
Recruiting
University of California Los Angeles
Los Angeles, California, 90095
Hamiya Askaryar, 424-365-4129, haskaryar@mednet.ucla.edu
Not yet recruiting
Ada West Research, LLC
Meridian, Idaho, 83646
Stacy Gonzales, 208-279-1520, research@adawestdermatology.com
Recruiting
Quality Care Clinical Research
Miami, Florida, 33101
Mariano Sanso, 305-906-1994, msanso@qualitycareclinicalresearch.com
Recruiting
FXM Clinical Research Miami, LLC
Miami, Florida, 33155
FXM Administrative, 954-368-4406, info@fxmresearch.com
Recruiting
Sadick Research Group, LLC
New York, New York, 10021
Zoe Ataker, 212-772-7243, zoe.ataker@sadickdermatology.com
Recruiting
Eminent Clinical Research and Associates
North Lauderdale, Florida, 33068
Marie Moore, 954-366-5373, admin@eminentclinicalresearch.com
Not yet recruiting
Ziaderm Research LLC
North Miami Beach, Florida, 33162
Tory Sullivan, 305-652-8600, drtory@sullivandermatology.com
Recruiting
Northridge Clinical Trials
Northridge, California, 91325
Evelyn Jasso, 818-350-7483, ejasso@northridgetrials.com
Recruiting
Chesapeake Clinical Research, Inc
Pasadena, Maryland, 21122
Jonathan Matz, 410-931-1966, jonathanmatz@yahoo.com
Recruiting
Saguaro Dermatology Associates
Phoenix, Arizona, 85018
Dathan Hamann, 480-562-3610, clinicaltrials@saguaroderm.com
Recruiting
UPMC Department of Dermatology
Pittsburgh, Pennsylvania, 15213
Charity Ruhl, 412-647-2013, ruhlcl@upmc.edu
Not yet recruiting
Skin Cancer and Dermatology Institute
Reno, Nevada, 89509
Jennifer Craddock, 775-336-3665, Jdiaz@skincancerderm.com
Recruiting
Integrative Skin Science and Research
Sacramento, California, 95815
Sydney Fong, 916-524-1216, recruitment@integrativeresearch.com
Recruiting
Progressive Clinical Research, PA
San Antonio, Texas, 78213
Jamie Renker, 210-614-5557, jrenker@progclin.com
Recruiting
Georgia Skin & Cancer Center
Savannah, Georgia, 31406
Dr. Sidney Smith, 912-925-0067, sidney.smith@elligodirect.com
Not yet recruiting
Endeavor Health
Skokie, Illinois, 60077
Karla Radillo Mendoza, 847-663-8530, karla.radillomendoza@endeavorhealth.com
Not yet recruiting
NMC Research LLC
Tampa, Florida, 33614
Dr Thomas M Taylor, 813-374-0568, Researchteam@nmc-research.com
Not yet recruiting
Valiance Clinical Research - Tarzana
Tarzana, California, 91356
Jesse Padilla, 213-880-1730, j.padilla@valianceclinicalresearch.com
Not yet recruiting
Paradigm Clinical Research Centers, LLC: Wheat Ridge
Wheat Ridge, Colorado, 80033
Cassandra Clayton, 303-463-1947, cclayton@paradigm-research.com
Recruiting

Other trials in United States

Poland14 sites, 14 recruiting

NZOZ Centrum Medyczne KERmed
Bydgoszcz
Not yet recruiting
OptiTrial
Chojnice
Not yet recruiting
Dermedea Clinic
Gdansk
Not yet recruiting
CM Pratia Katowice
Katowice
Not yet recruiting
Provita Sp. z o. o.
Katowice
Not yet recruiting
Klinika Zdybski - Dermedic (Kielce)
Kielce
Not yet recruiting
Clinical Best Solution Sp. z o.o.
Lublin
Not yet recruiting
NZOZ Hipokrates
Piotrkow Trybunalski
Not yet recruiting
Twoja Przychodnia Poznanskie Centrum Medyczne Sp.
Poznan
Not yet recruiting
Laser Clinic S.C. Andrzej Krolicki, Tomasz Kochanowski
Szczecin
Not yet recruiting
Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.
Szczecin
Not yet recruiting
Klinika Ambroziak Dermatologia
Warsaw
Not yet recruiting
Medicus Clinic
Wroclaw
Not yet recruiting
Softskin Medical Center Dr Elzbieta Wojtowicz-Prus
Wroclaw
Not yet recruiting

Other trials in Poland

Canada9 sites, 9 recruiting

Beacon Dermatology
Calgary, Alberta
Not yet recruiting
Laser Rejuvenation Clinics Edmonton D.T. Inc.
Calgary, Alberta
Not yet recruiting
Laser Rejuvenation Clinics Edmonton D.T. Inc.
Edmonton, Alberta
Angela Tycholaz, 5874095160, tycholaza@rejuv.ca
Recruiting
Rejuvenation Dermatology Clinic Edmonton South
Edmonton, Alberta
Angela Tycholaz, 5877604265, tycholaza@rejuv.ca
Recruiting
DermEdge Research
Mississauga, Ontario
Mark Lomaga, +1 905 274 9999, drlomaga@dermedge.com
Recruiting
Saskatoon Dermatology Centre
Saskatoon, Saskatchewan
Kyle Cullingham, +1 306-373-0040, kcullingham@nosm.ca
Recruiting
Centre de Recherche Saint-Louis (Sherbrooke)
Sherbrooke, Quebec
Evelyn Chinchilla, 1-888-728-9142, eachinchilla@recherchestlouis.com
Recruiting
FACET Dermatology
Toronto, Ontario
Not yet recruiting
North York Research Inc.
Toronto, Ontario
North York Research Inc., 416-222-7546, maryam@bnderm.com
Recruiting

Other trials in Canada

Germany7 sites, 7 recruiting

Fachklinik Bad Bentheim
Bad Bentheim
Not yet recruiting
University Hospital Dresden
Dresden
Not yet recruiting
Universitatsklinikum Frankfurt Klinik fur Dermatologie, Venerologie und Allergologie
Frankfurt
Not yet recruiting
Dermatologikum Hamburg GmbH
Hamburg
Not yet recruiting
University of Luebeck
Lübeck
Not yet recruiting
University Hospital of Muenster
Münster
Not yet recruiting
Hautarztpraxis Dr. Hoffmann
Witten
Not yet recruiting

Other trials in Germany

Czechia6 sites, 6 recruiting

CCR Ostrava s.r.o.
Ostrava
Not yet recruiting
Pratia Pardubice a.s.
Pardubice
Not yet recruiting
Clintrial s.r.o.
Prague
Not yet recruiting
Fakultni Nemocnice Kralovske Vinohrady
Prague
Not yet recruiting
Praglandia s.r.o.
Prague
Not yet recruiting
Pratia Prague
Prague
Not yet recruiting

Other trials in Czechia

Hungary6 sites, 6 recruiting

Trial Pharma Kft.
Békéscsaba
Not yet recruiting
Dept. Dermatology, Venereology and Dermatooncology, Semmelweis University
Budapest
Not yet recruiting
Debreceni Egyetem - Orvos es Egeszsegtudomanyi Centrum (DEOEC) (University of Debrecen Medical and Health Science Center)
Debrecen
Not yet recruiting
Pecsi Tudomanyegyetem
Pécs
Not yet recruiting
Komplex Labor Kft
Szeged
Not yet recruiting
University of Szeged
Szeged
Not yet recruiting

Other trials in Hungary

Bulgaria5 sites, 5 recruiting

Medical Center Medconsult Burgas EOOD
Burgas
Not yet recruiting
Medical Center Kazanlak EOOD
Kazanlak
Not yet recruiting
Medical Center Medconsult Pleven-Lovech Branch
Lovech
Not yet recruiting
Medical Center Medconsult Pleven OOD
Pleven
Not yet recruiting
Medical Centre Pratia Clinic EOOD
Varna
Not yet recruiting

Other trials in Bulgaria

Spain5 sites, 5 recruiting

Hospital General Universitario Dr. Balmis
Alicante
Not yet recruiting
Hospital Universitari Germans Trias i Pujol
Badalona
Not yet recruiting
Hospital Universitario La Paz
La Paz
Not yet recruiting
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela
Not yet recruiting
Hospital Universitario Miguel Servet
Zaragoza
Not yet recruiting

Other trials in Spain

About this study

Official title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

Read the detailed description

This study contains two parts: Part 1 and Part 2.

Part 1 (24-Week Placebo-controlled Period):

Eligible patients will be randomized in a 1:1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2, camoteskimab dose 3 or placebo.

Part 2 (Extension Period):

In part 2, all participants will receive camoteskimab.

This study will enroll both treatment-naive participants and those with an inadequate response to previous biologic therapy.

Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema
Being tested: Camoteskimab, Placebo
Medical subject headings: Dermatitis, Atopic, Dermatitis, Skin Diseases, Eczema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

CamoteskimabDrug
Also called APL-9109
Drug Product
PlaceboDrug
Inactive substance

Study groups in NCT07599813
Study group	Role	What they receive
Camoteskimab Dose Level 1	Experimental	Camoteskimab administered subcutaneously Receives: Drug: Camoteskimab
Camoteskimab Dose Level 2	Experimental	Camoteskimab administered subcutaneously Receives: Drug: Camoteskimab
Camoteskimab Dose Level 3	Experimental	Camoteskimab administered subcutaneously Receives: Drug: Camoteskimab
Placebo	Placebo comparator	Dummy version of the study drug administered subcutaneously Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Percentage change from baseline in Eczema Area and Severity Index (EASI) between camoteskimab and placebo at Week 24
An EASI score is a tool used to measure the extent (area) and severity of atopic eczema. The EASI utilizes area assessments that rate the four involved regions on a 0% to 100% scale for each region. The scores are added up for each of the four body regions (head, arms, trunk, and legs). For each of these components, the individual scores are added together to calculate the EASI score, which ranges from 0 to 72. The higher the EASI score, the more severe the AD.
Measured: From Baseline visit until Week 24 visit

Secondary outcomes (3)

Proportion of participants achieving at least 75% improvement from baseline in EASI (EASI-75)
To further assess the efficacy of camoteskimab in participants with moderate-to-severe AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).
Measured: 24 weeks
Proportion of participants with vIGA-AD 0/1 and a decrease in vIGA-AD of ≥ 2 points from baseline
To further assess the efficacy of camoteskimab in participants with moderate-to-severe AD via Validated Investigator's Global Assessment Scale, which provides a global clinical assessment of AD severity
Measured: 24 weeks
Proportion of participants with an improvement of ≥ 4 or more points from baseline in peak pruritus NRS (PP-NRS) weekly average of the daily scores
To further assess the efficacy of camoteskimab in participants with moderate-to-severe AD via the Peak Pruritus Numerical Rating Scale, which assesses itch severity.
Measured: 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

28 May 202630 Apr 2028

First posted20 May 2026
Study start28 May 2026
Primary completion31 Oct 2027 (estimated)
Study completion30 Apr 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Atopic DermatitisStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 280 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07599813
Sponsor's protocol ID: AP43CP04
Status last verified: Aug 2026
First submitted: 15 May 2026
Last updated: 28 Aug 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No

Interested in taking part?

Each site lists its own contact. Pick the site nearest to you.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis

All Atopic Dermatitis trials

Study at a glance

From the registry record, last updated by the sponsor on 28 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
ClinicalTrials.gov ID: NCT07599813
Acronym / sponsor ID: AP43CP04
Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema
Phase: Phase 2
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 280 participants (estimated)
Lead sponsor: Apollo Therapeutics LtdIndustry (pharma, biotech, devices)
Study start: 28 May 2026 (actual)
Primary completion: 31 Oct 2027 (estimated)
Study completion: 30 Apr 2028 (estimated)
First posted: 20 May 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

Detailed description

This study contains two parts: Part 1 and Part 2.

Part 1 (24-Week Placebo-controlled Period):

Eligible patients will be randomized in a 1:1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2, camoteskimab dose 3 or placebo.

Part 2 (Extension Period):

In part 2, all participants will receive camoteskimab.

This study will enroll both treatment-naive participants and those with an inadequate response to previous biologic therapy.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 4

Arm	Type	Receives
Camoteskimab Dose Level 1	Experimental	Drug: CamoteskimabCamoteskimab administered subcutaneously
Camoteskimab Dose Level 2	Experimental	Drug: CamoteskimabCamoteskimab administered subcutaneously
Camoteskimab Dose Level 3	Experimental	Drug: CamoteskimabCamoteskimab administered subcutaneously
Placebo	Placebo comparator	Drug: PlaceboDummy version of the study drug administered subcutaneously

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (10 listed)

Age 18-65 inclusive, at the time of signing the informed consent.
Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.
Participants with moderate-to-severe AD defined by:
Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks.
Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Key exclusion criteria (35 listed)

History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.
Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.
Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.
Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.
Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
CamoteskimabAlso: APL-9109Drug Product	Drug	Camoteskimab Dose Level 1, Camoteskimab Dose Level 2, Camoteskimab Dose Level 3
PlaceboInactive substance	Drug	Placebo

Primary outcome

Percentage change from baseline in Eczema Area and Severity Index (EASI) between camoteskimab and placebo at Week 24
Time frame: From Baseline visit until Week 24 visit
An EASI score is a tool used to measure the extent (area) and severity of atopic eczema. The EASI utilizes area assessments that rate the four involved regions on a 0% to 100% scale for each region. The scores are added up for each of the four body regions (head, arms, trunk, and legs). For each of these components, the individual scores are added together to calculate the EASI score, which ranges from 0 to 72. The higher the EASI score, the more severe the AD.

3 secondary outcomes

Proportion of participants achieving at least 75% improvement from baseline in EASI (EASI-75)
Time frame: 24 weeks
Proportion of participants with vIGA-AD 0/1 and a decrease in vIGA-AD of ≥ 2 points from baseline
Time frame: 24 weeks
Proportion of participants with an improvement of ≥ 4 or more points from baseline in peak pruritus NRS (PP-NRS) weekly average of the daily scores
Time frame: 24 weeks

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2026.

Related trials for Atopic Dermatitis

Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AllerVie Clinical Research

Birmingham, United States

205-209-4101

ACRAdmin@allervie.com

Cahaba Dermatology and Skin Health Center

Birmingham, United States

205-778-1564

jperry@cahabaderm.com

Saguaro Dermatology Associates

Phoenix, United States

480-562-3610

clinicaltrials@saguaroderm.com

85 sites in 8 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Camoteskimab in people with Atopic Dermatitis and Atopic, run by Apollo Therapeutics Ltd at 85 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 85 sites in United States, Poland, Canada, Germany, Czechia and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage change from baseline in Eczema Area and Severity Index (EASI) between camoteskimab and placebo at Week 24 (time frame: From Baseline visit until Week 24 visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07599813.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.